Genentech’s Activase (alteplase)
Executive Summary
In the year since the release of the preliminary results of ISIS-3, Genentech's marketshare has fallen to "just over half of all patients administered thrombolytic therapy in the U.S.," Genentech reports. "In the [U.S.], approximately 53% of patients currently treated with thrombolytics receive alteplase, 36% are prescribed streptokinase, and 11% receive APSAC.